Based on these findings, a multicenter randomized phase II study is currently underway exploring the combination of dalantercept plus axitinib vs axitinib plus placebo in patients with advanced RCC refractory to anti-VEGF therapy. Here, VEGFA is linked to renal cell carcinoma.